Michael Polansky is training an AI model on skin that’s still alive

Michael Polansky, known as Lady Gaga's partner and a former Sean Parker associate, has revealed a stealth AI startup that sustains living human skin tissue outside the body for weeks at a time, using the platform to identify promising new skincare ingredients through machine-learning analysis.

Michael Polansky has stepped out of the shadows to reveal a years-long venture at the intersection of biotechnology and artificial intelligence. His startup maintains living human skin samples viable outside the body for extended periods — weeks rather than the usual hours — creating a testing ground to screen potential skincare compounds with far greater biological accuracy than traditional lab methods allow.

Polansky is widely recognized in pop culture circles as Lady Gaga's partner, but he also has deep Silicon Valley roots as a former senior figure in Sean Parker's orbit. His new company represents a pivot toward longevity and cosmetic science, using AI to analyze how living tissue responds to various compounds and accelerate the discovery of effective skincare ingredients.

The disclosure marks the first time Polansky has spoken openly about the project, suggesting the company may be approaching a stage where outside investment, partnerships, or commercial launches are on the horizon.

Michael Polansky has quietly devoted several years to building a startup that sits at an unusual crossroads: keeping human skin literally alive outside the body while deploying artificial intelligence to mine that tissue for skincare breakthroughs. The company has only now broken its silence, suggesting a deliberate stealth period during which the core technology was developed and validated before any public exposure.

The central innovation is tissue longevity. Conventional skin samples used in cosmetic and pharmaceutical testing typically remain viable for only a short window, limiting how much data researchers can gather. By extending that window to weeks, Polansky's platform allows scientists and AI systems to observe how living skin tissue reacts to candidate compounds over a much longer and more meaningful timeframe — capturing responses that short-lived samples would never reveal.

Artificial intelligence ties the system together by processing the biological data generated from these extended experiments, identifying patterns in how different ingredients interact with living tissue. The goal is to dramatically accelerate the pipeline from raw compound discovery to a finished skincare product, replacing years of iterative lab work with faster, data-driven insights.

Why it matters: The global skincare industry is enormous and notoriously slow to innovate at a biological level, often relying on ingredient combinations that have been around for decades. A platform that can run high-fidelity, AI-assisted experiments on genuinely living tissue could reshape how effective compounds are discovered, potentially producing formulations that are both more scientifically validated and developed in a fraction of the usual time. It also raises interesting ethical and regulatory questions about the sourcing and use of living human tissue in commercial research.

Polansky's background adds an unusual dimension to the story. Long associated with Sean Parker — the Napster co-founder and early Facebook president — he brings a tech-disruption mindset to an industry more accustomed to traditional chemistry. His public emergence now likely signals that the company is approaching an inflection point, whether that means seeking major investment, forging partnerships with established beauty or pharmaceutical players, or preparing a commercial product launch.